natgillin/translations-raw huggingface dataset:
Some embodiments further comprise reacting Compound (K) or a pharmaceutically acceptable salt thereof with acetaldehyde in the presence of a palladium catalyst comprising a mixture of bis(dibenzylideneacetone) palladium and a tertiary phosphine ligand, PR3, wherein R is C1-6 alkyl or C5-6 cycloalkyl to form Compound (M) 
"NH, (K) ili njegove farmaceutski prihvatljive sol, s acetaldehidom u prisutnosti paladijskog katalizatora koji uključuje smjesu bis(dibenzilidenaceton)paladija s tercijarnim fosfinskim ligandom, PR*, gdje je R C,4 alkil ili Cs4 cikloalkil, kako bi se dobilo Spoj (M) x1 La) pe N
The polymer hydrogel of claim 8 having a swelling ratio in distilled water of 50 to 250. 
Polimerni hidrogel u skladu s patentnim zahtjevom 8, naznačen time da ima udio bubrenja u destiliranoj vodi od 50 do 250.
providing an aminooxy compound comprising a second reactive group, wherein the aminooxy compound is chosen from compounds of Formula III: wherein n is chosen from integers ranging from 1 to 10, P is chosen from amino protecting groups, and Y is a second reactive group; and 
A N Formula II pri čemu n je odabran od cijelih brojeva u rasponu od 1 do 10, P je odabran od amino zaštitnih skupina, i Y je druga reaktivna skupina; i
the cell is capable of migrating to a specific, damaged tissue in a patient; 
(a) stanica posjeduje sposobnost migracije do specifičnog, oštećenog tkiva bolesnika;
a saccharification wherein the liquefied lignocellulosic material is hydrolysed in the at least first container and/or in at least a second container. 
korak saharifikacije pri čemu ukapljeni lignocelulozni materijal hidrolizira barem u prvom spremniku i/ili barem u drugom spremniku.
the transaction identifier related to the transaction step is attached to the key of the data item (D1), and 
- < Pokazatelj prijenosa koji se odnosi na korak prijenosa priložen je ključu podatkovne stavke (D1) 1
The management system as claimed in claim 1, wherein the management system is continuous. 
Sustav za upravljanje prema patentnom zahtjevu 1, naznačen time da je sustav upravljanja kontinuiran.
(C1-C2)-alkylene-heteroaryl, wherein said heteroaryl ring is a five-or six-membered ring containing 1, 2, 3 or 4 heteroatoms selected from O, S or N; and wherein said heteroaryl ring is unsubstituted or mono-substituted by oxo (=O); 
(C1-C2)-alkilen-heteroaril, pri čemu je navedeni heteroarilni prsten petero-ili šestero-člani prsten koji sadrži 1, 2, 3 ili 4 heteroatoma koji su odabrani od O, S ili N; i pri čemu je navedeni heteroarilni prsten nesupstituiran ili mono-supstituiran s okso (=O);
The lighting module of claim 1, wherein said switching device is part of a boosting circuit. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni preklopni sklop dio sklopa za dodatno pojačavanje.
The method according to claim 2, wherein the machining is performed by a reaming drill. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se strojnu obradu provodi svrdlom za razvrtanje.
<400> 7 An immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid which is pneumolysin, diphtheria toxoid or CRM197 and 19F is conjugated to a second bacterial toxoid which is diphtheria toxoid or CRM197 and further comprising conjugates of S. pneumoniae capsular saccharides 4, 6B, 9V, 14, 18C, 23F, 1, 5 and 7F, wherein the average size of the 19A saccharide is between 110 and 700 kDa. 
Imunogeni pripravak, naznačen time što sadrži konjugate saharida iz kapsule bakterije S. pneumonijae iz serotipova 19A i 19F, gdje je 19A konjugiran s prvim bakterijskim toksoidom, koji je pneumolizin, difterijski toksoid ili CRM197, a 19F je konjugiran s drugim bakterijskim toksoidom, koji je difterijski toksoid ili CRM197, te što dodatno sadrži konjugate saharida 4, 6B, 9V, 14, 18C, 23F, 1, 5 i 7F iz kapsule bakterije S. pneumonijae, gdje je prosječna veličina saharida 19A između 110 1 700 kDa.
In a certain embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 2; a heavy chain variable region CDR2 of SEQ ID NO: 9; a heavy chain variable region CDR3 of SEQ ID NO: 16; a light chain variable region CDR1 of SEQ ID NO: 23; a light chain variable region CDR2 of SEQ ID NO: 30; and a light chain variable region CDR3 of SEQ ID NO: 37. 
(a) CDRI varijabilno područje jakog lanca od SEQ ID NO:2; CDR2 varijabilno područje jakog lanca od SEQ ID NO:9; CDR3 varijabilno područje jakog lanca od SEQ ID NO:16; CDRI varijabilno područje slabog lanca od SEQ ID NO:23; CDR2 varijabilno područje slabog lanca od SEQ ID NO:30; i CDR3 varijabilno područje slabog lanca od SEQ ID NOQO:37; ili
<400> 322 A diabody molecule comprising a first polypeptide chain and a second polypeptide chain, the polypeptide chains being covalently bonded to one another, wherein: 
PATENTNI ZAHTJEVI 1. >- Molekula diatijela koja sadrži prvi polipeptidni lanac i drugi polipeptidni lanac, polipeptidni lanci su kovalentno vezani jedan s drugim, pri čemu:
The collection according to any one of the preceding claims, wherein said antibodies or functional fragments thereof comprise CDR1 regions consisting of germline protein sequences from the respective variable heavy chain and variable light chain pairs. 
Zbirka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što navedena protutijela, ili njihovi funkcionalni fragmenti, sadrže područja CDR1 koja se sastoje od sljedova proteina iz zametne linije iz odgovarajućih parova varijabilnih teških lanca s varijabilnim lakim lancima.
The pharmaceutical composition according to the use of claim 8, wherein said pharmaceutical composition comprises an amount of from 1 mg to 100 mg, more preferably from 5 mg to 50 mg, of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, wherein the composition is for systemic administration. 
Farmaceutski sastav za uporabu prema zahtjevu 8, naznačen time, da spomenuti farmaceutski sastav obuhvaća benzidamin ili njegove fiziološki prihvatljive kiselinske adicijske soli, izražen/e u obliku slobodne baze, u količini od 1 mg do 100 meg, najpoželjnije od 5 mg do 50 mg, kada je sastav za sustavnu primjenu.
The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition comprises from 300 to 1200 mg of bindarit, and an amount of at least one compound selected from the group consisting of ramipril, losartan, irbesartan, amlodipine, verapamil, diltiazem and simvastatin showed in the following table A1: 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da navedeni farmaceutski sastav obuhvaća od 300 do 1200 mg bindarita, 1 jednu količinu od najmanje jednog spoja odabranog iz skupine koju čine ramipril, losartan, irbesartan, amlodipin, verapamil, diltiazem 1 simvastatin, prema prikazanim vrijednostima u sljedećoj tablici A1:
The composition of claim 14, wherein said additional anti-hepatitis C virus agent is an inhibitor of hepatitis C virus helicase, polymerase, metalloprotease, or IRES. 
Pripravak u skladu s patentnim zahtjevom 14, naznačen time, da je rečeno dodatno sredstvo protiv virusa hepatitisa C inhibitor helikaze, polimeraze, metaloproteaze ili IRES virusa hepatitis C.
converting the product of step (c) to 
(d) prevođenju produkta iz koraka (c) u
The method according to claim 1, further comprising stabilizing the C5S2$ by adding one or more foreign ions selected from the group consisting of halogens, nonmetals, alkali and alkaline earth metals, substances from the transition metals and metalloids, and metals to crystal structure of C5S2$. 
Postupak sukladno zahtjevu 1 ili 2, naznačen time što C5S2$ je stabiliziran dodavanjem jednog ili više stranih iona iz skupine halogena, nemetala, alkalijskih i zemnoalkalijskih metala kao i supstanci iz skupine vodiča i metaloida i metala kristalne strukture.
A pharmaceutical tablet formulation, comprising per 600 mg tablet the following ingredients: 
Farmaceutska formulacija tablete, naznačena time, da sadrži po 600 mg tableti slijedeće sastojke:
A method as in claim 1, wherein in the case that a configuration of the "handling rules" is defined externally by a server and distributed to the involved RAN (201) nodes, the distribution is made by means of "handling labels". 
Postupak prema zahtjevu 1, gdje u slučaju kada je konfiguracija "pravila upravljanja" ("handling rules") definirana eksterno od strane poslužitelja 1 distribuirana čvorovima uključenih pristupnih radio mreža RAN (201), distribucija ide putem "upravljačkih oznaka" ("handling labels").
is hydrogen, methyl, or 2-hydroxy-ethyl, or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which 
R612 je vodik, metil ili 2-hidroksietil, ili R611 i R612, zajedno s i uključivši atom dušika na kojeg su vezani, tvore heterociklički prsten Hetl, gdje
The process according to claim 26, wherein the temperature in the first insulator is in a range of approximately 20° to approximately 50° C. and the temperature in the second insulator is in a range of approximately -5° to approximately +25° C. 
. Postupak prema Zahtjevu 26, naznačen time da je temperatura u prvom izolatoru u rasponu od približno 20 do približno 50" i temperatura u drugom izolatoru je u rasponu od približno -5 do približno +25"C.
A compound of Formula 1, or salt thereof, wherein 
Spoj formule 1, njegov N-oksid ili sol, u kojima
Thus, it is an object of the present invention to provide a metal packaging which is adapted for and can be packed in traditional automated packing machines in order to avoid the need for investing additional, very substantial sums of money in the development and implementation of new automated packing machines. 
Dakle, jedan cilj predmetnog izuma je taj, da se osigura metalno pakiranje koje je prilagođeno za pakiranje u tradicionalnim automatiziranim strojevima za pakiranje i tamo može biti pakirano, i da bi se time spriječila potreba za dodatnim investicijama koje predstavljaju vrlo značajne iznose novca za razvoj i za ugradnju novih automatiziranih strojeva za pakiranje.
The method of claim 14, wherein the amount of base added is at least sufficient to neutralize at least 10% of the carboxylic acid groups in the polycarboxylic acid polymer. 
Postupak za koji se traži zaštita patentom u patentnom zahtjevu 13, pri čemu je dodana količina baze najmanje dovoljna da neutralizira bar 90% skupina karboksilne kiseline u polimeru polikarboksilne kiseline.
Speed of rotation of the blades: 50 rpm±2 rpm 
Datum podnošenja europske prijave patenta:
The solid form of claim 9, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 279 °C, optionally having a thermal gravimetric analysis plot comprising a mass loss of less than about 6% when heated from about 25 °C to about 150 °C, optionally wherein the solid form exhibits a mass increase of less than about 0.5% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što ima grafički prikaz toplinske gravimetrijske analize koji sadrži gubitak mase manji od otprilike 0,5% prilikom grijanja od otprilike 25°C do otprilike 150°C.
The composition of any one of claims 1, or 6 to 10, or 12 to 16, or the method of any one of claims 4, or 6 to 16, or the kit of any one of claims 5 to 10, or 12 to 16, wherein the heterologous polypeptide has enzymatic activity that modifies a polypeptide associated with DNA, which activity is histone-modifying activity. 
Sastav prema bilo kojem od zahtjeva 1, ili 6 do 10, ili 12 do 16, ili postupak u skladu s bilo kojim od zahtjeva 4, ili 6 do 16, ili garnitura prema bilo kojem od zahtjeva 5 do 10, ili 12 do 16, naznačen/a time, da heterologni polipeptid ima enzimsko djelovanje koje modificira polipeptid povezan s DNK, pri čemu se tu radi o djelovanju histonske modifikacije.
A pharmaceutical composition comprising a compound as described in any one of claims 1-13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and optionally an additional therapeutic agent, wherein the additional therapeutic agent is an HIV protease inhibiting compound, an HIV non-nucleoside inhibitor of reverse transcriptase, an HIV nucleoside inhibitor of reverse transcriptase, an HIV nucleotide inhibitor of reverse transcriptase, an HIV integrase inhibitor, a gp41 inhibitor, a CXCR4 inhibitor, a gp120 inhibitor, a CCR5 inhibitor, a capsid polymerization inhibitor, or a non-catalytic site HIV integrase inhibitor and combinations thereof. 
Spoj kao što je opisano u bilo kojem od zahtjeva 1-26, ili njegova farmaceutski prihvatljiva sol, u kombinaciji s terapeutski učinkovitom količinom dodatnog terapeutskog sredstva, pri čemu je dodatno terapeutsko sredstvo spoj koje inhibira HIV proteazu, HIV ne-nukleozidni inhibitor reverzne transkriptaze, HIV nukleozidni inhibitor reverzne transkriptaze, HIV nukleotidni inhibitor reverzne transkriptaze, inhibitor HIV integraze, inhibitor gp41, inhibitor CKSCR4, inhibitor gp120, inhibitor CCR5, inhibitor polimerizacije kapsida, ili inhibitor ne-katalitičkog mjesta HIV integraze i njihove kombinacije, naznačen time što je upotrebu za liječenje HIV infekcije.
Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D. and Wallach. 
Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D. i Wallach.
The combined extract was cooled to 0 to 5°C., acidified slowly to a pH below 1.0 with concentrated HCI and extracted with ethyl acetate (4 x 1 I. 
Spojeni ekstrakt se ohladi na 0 do 5C, zakiseli se lagano na pH ispod 1.0 sa koncentriranom HC1 i ekstrahira se sa etilacetatom (4x1 1.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 together with a pharmaceutically accepted carrier or excipient. 
Farmaceutski sastavi, naznačeni time, da obuhvaćaju terapeutski učinkovitu količinu spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, zajedno s farmaceutski prikladnim nosačem ili pomoćnim sredstvima.
The pharmaceutical composition for use according to claim 17 or 18, wherein the agent is a cytotoxic agent. 
Farmaceutski sastav za uporabu prema zahtjevu 20, naznačen time, da navedeni rak je gliom tumor.
domain (a) which is the functional fragment of a sequence of soluble hTRAIL protein, which fragment begins with an amino acid at a position not lower than hTRAIL95 or a homolog of said functional fragment having at least 70% sequence identity, and 
- domenu (a) koja sadrži funkcionalni fragment sekvence topivog h TRAIL proteina koja počinje s amino kiselinom na položaju ne nižem od hTRAIL95 i sposobna je inducirati apoptotski signal u stanicama sisavaca nakon vezanja na njegove receptore na površini stanica, ili homolog navedenog funkcionalnog fragmenta koji ima barem 70% identičnosti sekvence s navedenim funkcionalnim fragmentom; i
represents a hydrogen atom; and/or 
R3 predstavlja atom vodika; i/ili
A selective a7 nAChR agonist compound for use in treating or preventing drug-induced central nervous system disorders. 
Spoj prema zahtjevu 1 ili 2 za upotrebu u liječenju ili prevenciji poremećaja središnjeg živčanog sustava, upale, boli ili neovaskularizacije.
According to other embodiments heating device 207 may be a microwave heater. 
Sustav prema patentnom zahtjevu 2, naznačen time da je navedeni grijaći uređaj mikrovalni grijač.
wherein said antibody or antibody fragment blocks binding of human PD-L1 and human PD-L2 to human PD-1. 
Antitijelo ili fragment antitijela prema patentnim zahtjevima 1 do 12 za uporabu u postupku za liječenje kancera.
receiving (303), by the source eNB, the special data packet from the SGW, wherein the special data packet is generated by the SGW; regenerating (3031), by the source eNB, a special data packet with an end marker according to the special data packet sent by the SGW, wherein the regenerated special data packet does not contain user data and carries a PDCP sequence number of a next user data packet to be sent by the source eNB; 
Postupak prema zahtjevu 1, naznačen time da, prije prijema posebnog paketa podataka, postupak nadalje sadrži: prijem (303), od izvornog eNB, posebnog paketa podataka od SGW, pri čemu se poseban paket podataka generira pomoću SGW; i slanje, od izvornog eNB, posebnog paketa podataka prema ciljnom eNB.
The sole structure (100) according to claim 13, characterized in that said seal (116) comprises the gluing with pressing of said peripheral region (10a) to said upper portion (113). 
Struktura potplata (100) u skladu s patentnim zahtjevom 17, naznačena time, da navedeno brtvljenje (116) podrazumijeva lijepljenje pod pritiskom navedenog perifernom dijelu (10a) na spomenuti gornji dio (113).
A high purity diaminophenothiazinium compound of the following formula: 
Diaminofenotiazinski spoj visoke čistoće koji je predstavljen sljedećom formulom:
A process according to claim 16, characterised in that the atomiser (11) is formed as an inhaler, particularly for medical aerosol therapy. 
Postupak prema zahtjev 16, naznačen time, da je atomizer (11) izrađen kao inhalator, posebno za medicinsku terapiju s aerosolom.
Use of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a colorectal cancer, a head and neck cancer, a pancreatic cancer, a breast cancer, a gastric cancer, a bladder cancer, a vulvar cancer, a leukemia, a lymphoma, a melanoma, a renal cell carcinoma, an ovarian cancer, a brain cancer, an osteosarcoma, or a lung cancer. 
Upotreba spoja u skladu s patentnim zahtjevom I, ili njegove farmaceutski prihvatljive soli, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kolorektalnog rak, raka glave i vrata, raka gušterače, raka dojke, raka želuca, raka mokraćnog mjehura, raka stidnice, leukemije, limfoma, melanoma, karcinoma bubrežnih stanica, raka jajnika, raka na mozgu, osteosarkoma ili raka pluća. t>&
The rim of one of the preceding claims, wherein the internal portion (21) is made of a plastic material. 
Obruč prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je unutarnji dio (22) napravljen od plastičnog materijala.
RIA of FSH is done in a similar fashion as the assay for LH with substitution of the LH antibody by the FSH antibody diluted 1:30,000 and the labeled rLH by the labeled rFSH. 
RIA za FSH provedena je na sličan način kao ispitivanje za LH, uz zamjenu protutijela za LH protutijelom za FSH, razrijeđenim 1:30.000 i obilježenog rLH s obilježenim rFSH.
The best results were achieved, when octanoic acid was introduced into preservative solution. 
Najbolji rezultati su postignuti, kad je u otopinu konzervansa uvedena oktanoična kiselina.
The residue is diluted in CH2Cl2/H2O and filtered through a ChemElute cartridge. 
Ostatak se razrijedi u smjesi CH2C1/H20, te filtrira kroz uložak ChemElute.
At the next programmed change to the supply off period, the electrical power supply is stopped by the programmable electrical control device, whether or not the manual switch is in an on or off position. In the present specification, terms have been used which differ slightly from terms used in Australian Provisional Application No. 2012901567, from which the present application, in part, claims priority. 
Postupak za uporabu programabilnog električnog upravljačkog uređaja (10) sukladno zahtjevu 14, koji nadalje uključuje uporabu električnog prekidačkog uređaja (12), pri čemu je električni sklopni uređaj (12) u skladu s preambulom zahtjeva 1, radi stavljanje ručnog prekidača (16) bilo u položaj uključeno ili u položaj isključeno.
In addition, in the present invention, it is preferable that the phosphoric acid-activating compound is diimidazolyl pyrophosphate, and the phosphoric acid compound is UMP or a UMP salt. 
Postupak proizvodnje u skladu s patentnim zahtjevom 1, naznačen time, da je spoj za aktivaciju fosforne kiseline diimidazolil pirofosfat, a spoj fosforne kiseline je UMP ili sol UMP-a.
wherein and R2 are each independently selected from the group consisting of hydrogen and lower alkyl; 
R! i R" svaki neovisno izabrani iz skupine koja se sastoji od vodika i nižeg alkila;
Figure 10: Constructs of the invention. 
Datum podnošenja europske prijave patenta:
a fifth step wherein FVIII is incubated with the activated water soluble polymer and m-toluidine under conditions that allow conjugation of the activated water-soluble polymer to one or more oxidized carbohydrates on FVIII, said conditions comprising a time period of about 2 hours; a temperature of about 22 °C; the absence of light; and with stirring; and 
pri čemu uvjeti inkubiranja terapeutskog proteina s aktiviranim polimerom topljivim u vodi i nukleofilnim katalistom u petom koraku sadrže vremenski period od oko 2 sata; temperaturu od oko 22 °C; odsutnost svjetla; i s miješanjem; i pri čemu je agens za gašenje u šestom koraku L-cistein; i pri čemu je L-cistein dodan kako bi rezultirao krajnjom koncentracijom od oko 10 mM i uvjeti u šestom koraku sadrže vremenski period od oko 60 minuta, temperaturu od oko 22 °C, odsutnost svjetla i s miješanjem.
The antibody of claim 11, wherein said antibody has an increase in the fraction of non-fucosylated oligosaccharides attached to said glycoengineered Fc region. 
Antitijelo u skladu sa zahtjevom 9, naznačeno time, da najmanje 20% oligosaharida u Fc regiji navedenog polipeptida je dvosekcijsko, ne-fukozilirano.
The pharmaceutical composition of claim 8, wherein the compound of formula (I) is present in the polymorph I form in the composition in an amount equal to or more than 90 percent by weight of the total weight of the compound of formula (I) present in the composition. 
Farmaceutski pripravak prema zahtjevu 11 naznačen time da sadrži više od 90 posto težinski spoja formule (I) u polimorfu I u odnosu na ukupnu količinu spoja formule (I) koja se nalazi u pripravku. .
a pharmaceutically acceptable amount of an acetate salt of caspofungin; 
farmaceutski djelotvornu količinu acetatne soli kaspofungina;
The compound or pharmaceutically acceptable salt for use according to claim 1 or 2, wherein the compound is administered with a pharmaceutically acceptable carrier or excipient. 
Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol naznačen time da je za upotrebu u postupku liječenja infekcije virusom Filoviridae kod ljudi.
The compound according to the invention can also be used in formulations together with other active ingredients, e.g. for the treatment or prophylaxis of conditions involving infection by Helicobacter pylori of human gastric mucosa. 
Spoj prema ovom izumu može se rabiti u formulacijama skupa s drugim aktivnim sastojcima, za tretman ili profilaksu stanja koja obuhvaćaju infekcije ljudske želučane mikoze s Helicobacter pylori.
The method of claim 1, wherein the one or more first calibration data points form a calibration curve. The method of claim 1, wherein each of the one or more first calibration data points is determined from a histogram corresponding to a different calibration sample, wherein the histogram provides amounts of DNA fragments at a plurality of sizes, and wherein at least a portion of the plurality of calibration samples have different fractional concentrations of fetal DNA. 
Metoda prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, što: prva točka podataka za kalibraciju određuje frakcionalnu koncentraciju fetalne DNK koja odgovara kalibracijskoj vrijednosti prvog parametra; i točka podataka za kalibraciju se utvrđuje iz histograma koji odgovara različitom kalibracijskom uzorku, pri čemu histogram pruža količine fragmenata DNK u više veličina, i pri čemu najmanje jedan dio različitih kalibracijskih uzoraka ima različite frakcionalne koncentracije.
The PET container of claim 1 wherein the moisture content of the wall is from 1780 ppm to 1980 ppm when exposed to 100% RH at 96° C. 
PET posuda iz patentnog zahtjeva 1 gdje sadržaj vlage zida je od 1780 ppm do 1980 ppm kada je izložena relativnoj vlažnosti od 100% na 96?